Health Kick Podcast: Understanding immunotherapy, why the drug market dried up and Immutep’s profitable potential
Health & Biotech
share
Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast.
In this episode Tim chats with Marc Voigt, executive director and CEO of Immutep (ASX:IMM).
Formerly known as Prima Biomed, Immutep is developing cancer immunotherapies for a number of indications including metastatic breast cancer, lung cancer and head, neck and shoulder cancer.
These programs are both self-funded and in conjunction with partners that include Glaxosmithkline, Merck and Pfizer.
Immutep is also tackling non-cancer autoimmune diseases including rheumatoid arthritis, irritable bowel disease and multiple sclerosis.
The company’s lead compound, eftilagimod alpha or ‘efti, targets a protein called LAG-3 that regulates immune responses.
So tune in to hear the pair discuss all things immunotherapy.
On mobile? Click here to listen with Apple podcasts, here for Spotify or here for Google Podcasts.
Like to listen to podcasts through another app? Just search for The Health Kick Podcast with Tim Boreham and subscribe!
